ACCELERATED PUBLICATION
Host Recognition of Bacterial Muramyl Dipeptide Mediated through NOD2

IMPLICATIONS FOR CROHN'S DISEASE*

Naohiro InoharaDagger , Yasunori OguraDagger , Ana Fontalba§, Olga Gutierrez§, Fernando Pons, Javier Crespo, Koichi Fukase||, Seiichi Inamura||, Shoichi Kusumoto||, Masahito Hashimoto**, Simon J. FosterDagger Dagger , Anthony P. Moran§§, Jose L. Fernandez-Luna§¶¶, and Gabriel NuñezDagger ¶¶||||

From the Dagger  Department of Pathology and Comprehensive Cancer Center, The University of Michigan Medical School, Ann Arbor, Michigan 48109, the § Unidad de Genetica Molecular and  Instituto de Patologia Digestiva, Hospital Universitario Marques de Valdecilla, 39008 Santander, Spain, the || Department of Chemistry, Graduate School of Science, Osaka University, Machikaneyama 1-1, Toyonaka, Osaka 560-0043, Japan, the ** Department of Infectious Diseases and Tropical Medicine, Research Institute, International Medical Center of Japan, Tokyo 162-8655, Japan, the Dagger Dagger  Department of Molecular Biology and Biotechnology, University of Sheffield, Sheffield S10 2TN, United Kingdom, and the §§ Department of Microbiology, National University of Ireland, Galway, Ireland

Received for publication, December 4, 2002, and in revised form, December 23, 2002

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS AND DISCUSSION
REFERENCES

NOD2, a protein associated with susceptibility to Crohn's disease, confers responsiveness to bacterial preparations of lipopolysaccharide and peptidoglycan, but the precise moiety recognized remains elusive. Biochemical and functional analyses identified muramyl dipeptide (MurNAc-L-Ala-D-isoGln) derived from peptidoglycan as the essential structure in bacteria recognized by NOD2. Replacement of L-Ala for D-Ala or D-isoGln for L-isoGln eliminated the ability of muramyl dipeptide to stimulate NOD2, indicating stereoselective recognition. Muramyl dipeptide was recognized by NOD2 but not by TLR2 or co-expression of TLR2 with TLR1 or TLR6. NOD2 mutants associated with susceptibility to Crohn's disease were deficient in their recognition of muramyl dipeptide. Notably, peripheral blood mononuclear cells from individuals homozygous for the major disease-associated L1007fsinsC NOD2 mutation responded to lipopolysaccharide but not to synthetic muramyl dipeptide. Thus, NOD2 mediates the host response to bacterial muropeptides derived from peptidoglycan, an activity that is important for protection against Crohn's disease. Because muramyl dipeptide is the essential structure of peptidoglycan required for adjuvant activity, these results also have implications for understanding adjuvant function and effective vaccine development.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS AND DISCUSSION
REFERENCES

Innate immunity recognizes invading microbes and triggers a defense response in the host aimed at clearing the invading pathogen. Toll-like receptors (TLRs)1 expressed on the surface of myelomonocytic cells play an important role in the recognition of microbial components and activation of innate immunity (1). Each membrane-associated TLR recognizes pathogen-associated molecular patterns that are expressed on infectious agents (1). Nods, including NOD1 and NOD2, are members of another family of proteins that have been recently implicated in intracellular recognition of bacterial components (2, 3). NOD2 is composed of two NH2-terminal caspase-recruitment domains, a centrally located nucleotide-binding domain and multiple COOH-terminal leucine-rich repeats (LRRs), and is expressed in myelomonocytic and dendritic cells (4, 5). Three genetic variants within the coding region of NOD2, L1007fsinsC, G908R, and R702W, have been genetically associated with susceptibility to Crohn's disease in European and American populations (6-9). NOD2 has been shown to recognize preparations of lipopolysaccharides (LPS) and peptidoglycan (PGN) through its COOH-terminal LRRs (10), and this activity is deficient in the disease-associated variants (7). However, the precise bacterial structure recognized by NOD2 remains unknown. In this report we identified muramyl dipeptide (MDP) derived from peptidoglycan as the structure in bacteria recognized by NOD2.

    MATERIALS AND METHODS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS AND DISCUSSION
REFERENCES

Reagents-- LPS from Escherichia coli O55:B5 prepared by the phenol extraction method, further purified by gel-filtration chromatography, detoxified LPS, and purified lipid A were obtained from Sigma. LPS from Salmonella typhimurium was obtained from Sigma. PGN from Staphylococcus aureus was from Fluka-Chemie (Buchs, Germany). PGN from Bacillus subtilis was purified as reported (11). Pam3CysSerLys4, a synthetic bacterial lipoprotein analog (sBLP), was a gift of A. Zychlinsky (Max Planck Institute for Infection Biology, Berlin, Germany). MDP and their analogs MurNAc-L-alanyl-L-isoglutamine and MurNAc-D-alanyl-D-isoglutamine were obtained from Bachem (Torrance, CA). Molecules with two and four copies of GlcNAc-MurNAc attached to L-Ala-D-isoGln, and their counterparts lacking dipeptide were synthesized as reported (12). Briefly, the disaccharide glucosaminyl-beta (1-4)-muramic acid was prepared by stereoselective glycosylation of an N-Troc muramic acid acceptor with N-Troc-glucosaminyl trichloroacetimidate. The disaccharide was converted to both disaccharide acceptor and donor, which was then coupled together by the same glycosylation method to give a tetrasaccharide. Octasaccharide was obtained in a good yield in a similar manner. Introduction of the dipeptide moiety of L-alanyl-D-isoglutamine to 3-O-lactyl groups was performed by deprotection afforded by the peptidoglycan tetrasaccharide and octasaccharide fragments.

Transfection and NF-kappa B Activation Assay-- The plasmids pcDNA3- NOD2, pcDNA3-TLR4, and pDNA3-MD2 have been described (10). The plasmids expressing TLR1 and TLR6 have been reported (13) and were generously provided by Dr. A. Hajjar (University of Washington, Seattle). Expression plasmids producing NH2-terminal HA-tagged NOD2 variants P268S, P268S/R702W, and P268S/G908R were generated by the QuikChange XL site-directed mutagenesis kit (Stratagene, La Jolla, CA). P268S/L1007fsinsC was generated by a PCR method using P268S DNA as a template. The generated PCR products were cloned into the pMX-puro expression plasmid (14). The authenticity of the constructs were confirmed by DNA sequencing. Expression of NOD2 proteins in transfected cells was determined by immunoblotting using monoclonal anti-HA antibody (Babco, La Jolla, CA) as described (5). NF-kappa B activation assays were performed as described (10). LPS, PGN, and MDP derivaties were added to the cultures in the presence of calcium phosphate to allow their entry into the cells as reported (10). Results were normalized for transfection efficiency with values obtained with pEF-BOS-beta gal. Expression of NOD2 proteins in transfected cells was determined by immunoblotting using monoclonal anti-HA antibody (Babco, La Jolla, CA) as described (4).

Gel Filtration-- PGN from B. subtilus (0.4 mg) was digested with mutanolysin (Sigma) for 24 h. After centrifugation at 100,000 × g for 10 min and filtration with a 0.22-µm nitrocellulose filter, digested PGN was fractionated by Superose 12 gel-filtration column chromatography with 10 mM HEPES, 100 mM NaCl, pH 7.4. Purified bovine serum albumine, chicken egg lysozyme, and bovine cytochrome c were used as molecular size standards.

Genotype Analysis-- Peripheral blood was obtained from normal donors and Crohn's disease patients after informed consent according to Guidelines from the Committee for the Protection of Human Subjects at the Hospital Universitario Marques de Valdecilla. DNA was tested for the 3020insC NOD2 mutation using the SNaPshot method (Applied Biosystems, Foster City, CA) based on the dideoxy single-base extension of an unlabeled oligonucleotide primer (5'-GCCCTCCTGCAGGCCC-3').

Electrophoretic Mobility Shift Assay-- PBMNC were cultured for 1 h with 1 µg/ml LPS from S. typhimurium or 10 ng/ml MDP. Then cells were lysed and nuclear extracts were analyzed for the presence of NF-kappa B binding activity as described previously (5).

Real-time PCR Analysis-- Total RNA was prepared using TRIZOL reagent (Invitrogen). To assess mRNA expression, a quantitative PCR method was used as described previously (5). The generated cDNA was amplified by using primers for human IL-1beta , glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (5), and A1 (5'-CGGATGTGGATACCTATAAGG-3' and 5'-GTCATCCAGCCAGATTTAGG-3'). Quantitative real-time PCR was performed in a 7000 sequence detection system (Applied Biosystems). The ratio of the abundance of IL-1beta and A1 transcripts to that of GAPDH transcripts was calculated as described (5). Specificity of the PCR products was determined by melting curve analysis.

    RESULTS AND DISCUSSION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS AND DISCUSSION
REFERENCES

NOD2 was shown to mediate responsiveness to preparations of LPS and PGN (10). To further characterize the bacterial moiety recognized by NOD2, we used human embryonic kidney (HEK293T) cells and a NF-kappa B-dependent luciferase reporter to compare the ability of NOD2 and TLR4 to recognize LPS and PGN. Because NOD2 is an intracellular protein, we assessed NOD2 activity under culture conditions that allow the internalization of the bacterial components into the cells (10). Expression of NOD2 and TLR4 together with its co-factor MD2 conferred responsiveness to purified LPS prepared by phenol extraction as reported (7, 10), whereas only NOD2 induced the response to PGN (Fig. 1A). The lipid A moiety of LPS mediates TLR4/MD2 activation (15). Consistent with the latter, NOD2, but not TLR4, did respond to lipid A-depleted detoxified LPS prepared by alkaline treatment (Fig. 1A), whereas TLR4, but not NOD2, responded to purified lipid A (Fig. 1A). Notably, TLR4, but not NOD2, was stimulated by highly purified LPS prepared by gel-filtration chromatography (Fig. 1A). These results indicate that TLR4 and NOD2 recognize different bacterial components and suggest that PGN present in LPS preparations may contain the moiety recognized by NOD2. To further characterize the bacterial structure recognized by NOD2, we digested purified PGN with the muramidases mutanolysin or Cellosyl, which degrade the glycan chains and result in the generation of muropeptides which are composed of N-acetylglucosamine (GlcNAc) and N-acetylmuramic acid (MurNAc) linked to short peptides (16). Digested PGN was fractionated by gel-filtration chromatography. Analysis of each fraction revealed a major peak of NOD2-stimulating activity induced by mutanolysin digestion with a relative molecular mass of less than 12 kDa, consistent with that expected for muropeptides (Fig. 1B). Similar results were observed when PGN was digested with Cellosyl, which revealed a single peak of NOD2 stimulatory activity of less than 12 kDa.2


View larger version (30K):
[in this window]
[in a new window]
 
Fig. 1.   Recognition of peptidoglycan by NOD2. A, NOD2 and TLR4 recognize different bacterial components. HEK293T cells were transfected with 0.1 ng of pcDNA3-NOD2 (NOD2) or 3 ng of pcDNA3-TLR4-FLAG plus 3 ng of pcDNA3-MD2 (TLR4+MD2) or left untreated (-) in the presence of reporter pBxIV-luc and pEF-BOS-beta -gal as described (10). Eight hours post-transfection, 1 µg/ml LPS from E. coli O55:B5 prepared by the phenol extraction method (phenol), LPS further purified by gel-filtration chromatography (gel filt.), LPS prepared by the phenol extraction and alkaline-detoxified (aLPS), purified lipid A from E. coli O55:B5 LPS, or 5 µg/ml PGN from S. aureus were added with fresh medium. Twenty-four hours post-transfection kappa B-dependent transcription was determined as described (10). Values represent mean of normalized data ± S.D. of triplicate cultures. B, cells were stimulated with gel-filtration fractions of PGN from B. subtilis digested or undigested with Mutanolysin for 24 h and fractionated by gel filtration as described under "Materials and Methods." Mutanolysin alone did not stimulate NOD2 activity.2 The ability of 2-µl aliquot from each fraction to induce NOD2-dependent NF-kappa B activation is shown. Molecular weight markers corresponding to bovine serum albumin (68K), chicken egg lysozyme (20K), and bovine cytochrome c (12K) are indicated.

PGN-derived muropeptides derived from most bacterial species are composed of GlcNAc-MurNAc linked to short peptides, which include the conserved dipeptide L-Ala and D-isoGln or D-Glu (Fig. 2A). To determine more directly if muropeptides are recognized by NOD2, we used a panel of synthetic molecules with the structure of GlcNAc-MurNAc linked to L-Ala-D-isoGln, as well as muramyl dipeptide MurNAc-L-Ala-D-isoGln (MDP), which lacks GlcNAc (Fig. 2A). GlcNAc-MurNAc-L-Ala-D-isoGln stimulated NF-kappa B in a NOD2-dependent manner, whereas disaccharide GlcNAc-MurNAc in dimeric or tetrameric forms did not (Fig. 2B), indicating that amino acid residues are required for stimulation of NOD2. However, we cannot formally rule out that the lack of NOD2 response to GlcNAc-MurNAc in dimeric or tetrameric forms is due to poor internalization of the synthetic molecules into the cells. MDP induced potent stimulation of NOD2 (Fig. 2B), indicating that GlcNAc is not essential for stimulatory activity. To determine further the specificity of the recognition of MDP by NOD2, we tested the MDP analogs MurNAc-L-Ala-L-isoGln and MurNAc-D-Ala-D-isoGln. Notably, replacement of L-Ala for D-Ala or D-isoGln for L-isoGln eliminated the ability of MDP to stimulate NOD2, indicating stereoselective recognition (Fig. 2C). Thus, the core structure required for recognition of NOD2 is MurNAc attached to L-Ala and D-isoGln. TLR2 has been proposed to act as a surface receptor for PGN and certain bacterial lipoproteins including synthetic bacterial lipopeptide (sBLP) (17, 18). Therefore, we tested the ability of TLR2 and NOD2 to respond to MDP and sBLP. TLR2 mediated a cellular response to sBLP but not to MDP (Fig. 2D). Conversely, MDP, but not sBLP, stimulated NOD2 activity (Fig. 2D). In addition, we tested whether co-expression of TLR2 with TLR1 and/or TLR6 could mediate recognition of MDP. TLR2 in combination with TLR1, TLR6, or TLR1/TLR6 did not activate NF-kappa B in response to MDP (Fig. 2D). Thus, NOD2 and TLR2 recognize different bacterial structures.


View larger version (25K):
[in this window]
[in a new window]
 
Fig. 2.   Stimulation of NOD2 by synthetic muropeptides. A, schematic representation of synthetic muropeptide structures used in the study. Molecules with two copies (2mer) or four copies (4mer) of GlcNAc-MurNAc with attached L-Ala-D-isoGln and their counterparts lacking dipeptide (2mer-aa, 4mer-aa) are shown. B, HEK293T cells were transfected with 66 ng of pMX-puro-Nod2 (NOD2) or vector control (-) and reporter pBxIV-luc and pEF-BOS-beta -gal plasmids. Eight hours post-transfection, the indicated amount of each compound was added to the cells and the ability of each compound to activate NF-kappa B was determined as indicated in the legend to Fig. 1. C, the ability of MDP and its analogs MurNAc-L-Ala-L-isoGln (LL) and MurNAc-D-Ala-D-isoGln (DD) at 100 ng/ml to stimulate NF-kappa B activation in the presence of NOD2 or control plasmid (-) was determined as in B. D, the ability of MDP (100 ng/ml) and sBLP (1000 ng/ml) to activate NF-kappa B was determined by transfection of 0.3 ng of pcDNA3-Nod2 (NOD2), 33 ng of pDisplay-TLR1, 33 ng of pDisplay-TLR6 or control plasmid (-) into HEK293 cells or in HEK293 cells stably transfected with TLR2 (TLR2) and reporter pBxIV-luc and pEF-BOS-beta -gal plasmids as described in B. Values represent the mean of normalized data ± S.D. of triplicate cultures.

The NOD2 variants associated with Crohn's disease, R702W, G908R, and L1007fsinsC, occur on the same haplotype background, which includes the common P268S polymorphism (6, 7). To compare the ability of normal and mutant NOD2 proteins to induce NF-kappa B activity in response to MDP, we expressed the NOD2 proteins in cells and evaluated their activity in a functional assay. Both normal and P268S NOD2 induced similar levels of NF-kappa B activation in response to MDP (Fig. 3A), which is consistent with the observation that P268S is not genetically associated with disease (6, 7). In contrast, the P268S/R702W, P268S/G908R, and P268S/L1007fsinsC variants induced greatly reduced levels of NF-kappa B activation in response to MDP when compared with normal NOD2 (Fig. 3A). Notably, whereas the P268S/R702W and P268S/R702W point mutants retained some ability to respond to MDP, the truncated P268/L1007fsinsC protein did not respond at all concentrations of NOD2 and MDP tested (Fig. 3A). Immunoblotting analysis revealed that the normal and NOD2 mutants were appropriately expressed (Fig. 3B), indicating that the observed differences in MDP responses could not be explained by differential expression of the NOD2 constructs.


View larger version (40K):
[in this window]
[in a new window]
 
Fig. 3.   Activation of normal and Crohn's disease-associated NOD2 proteins by MDP stimulation. A, 1 × 105 HEK293T cells were transfected with the indicated amounts pMX-puro plasmid expressing normal NOD2 or mutants carrying P268S (PS), P268S/R702W (RW), P268S/G908 (GR), P268S/L1007fsinsC (insC), or empty plasmid (-). Eight hours post-transfection, the indicated amount of MDP (1-100 ng/ml) was added to the cultured cells, and at 24-h post-transfection NF-kappa B activity was determined as described in the legend to Fig. 1A. Values represent the normalized mean data ± S.D. of triplicate cultures. B, 1 × 106 HEK293T cells were transfected with the indicated amounts of plasmid expressing wild-type, mutant NOD2, or control plasmid (-), and cell extracts from equal number of cells were prepared at 24 h post-transfection. Immunoblotting analysis was performed with anti-HA antibody. C, PBMNC were stimulated with 1 µg/ml LPS from S. typhimurium (L), 10 ng/ml MDP (M) for 1 h, or left untreated (C). D, nuclear extracts were analyzed for the presence of NF-kappa B binding activity by EMSA as described (5). Nuclear extracts from LPS-stimulated cells were preincubated with antibody specific for p50 subunit of NF-kappa B to monitor the size of the NF-kappa B-DNA complex (lane labeled alpha p50). D and E, PBMNC were cultured with LPS or MDP for 6 h as in C, and total RNA was extracted and analyzed for expression of IL-1beta (D) and A1 (E) transcripts by quantitative real-time PCR. cDNA was amplified with specific primers for human IL-1beta , GAPDH as described (5) and A1 (5'-CGGATGTGGATACCTATAAGG-3' and 5'-GTCATCCAGCCAGATTTAGG-3'). The levels of IL-1beta and A1 transcripts normalized to that of GAPDH were expressed relative to those in untreated cells that were considered as base line (5). Histograms represent the mean ± S.D. of triplicate analyses. HT, heterozygous; HM, homozygous.

We next determined the role of NOD2 in the recognition of MDP by primary cells from normal and Crohn's disease patients. A panel of healthy and Crohn's disease individuals were genotyped for the disease-associated NOD2 alleles, and two individuals (one without clinical evidence of disease and one individual with Crohn's disease) who were homozygous for the loss-of-function L1007fsinsC mutation were identified. The identification of apparently healthy individuals homozygous for L1007fsinsC is expected in that the penetrance of the L1007fsinsC mutation is not complete (6-9). PBMNC that are known to express NOD2 were isolated, incubated with MDP or LPS, and NF-kappa B activation was assessed in nuclear extracts by an electrophoretic mobility shift assay (EMSA). Stimulation of PBMNC from individuals carrying normal or heterozygous NOD2 alleles with either LPS or MDP resulted in induction of the NF-kappa B-DNA complex (Fig. 3C). In contrast, PBMNC from individuals homozygous for L1007fsinsC did respond to LPS, but not to MDP (Fig. 3C). The DNA binding complex induced by MDP was shifted by incubation of the nuclear extracts with an antibody specific for the p50 subunit of NF-kappa B (Fig. 3C), indicating that the detected protein-DNA complex contained NF-kappa B. To further assess NF-kappa B activation, the mRNA levels of IL-1beta and A1, two NF-kappa B target genes expressed in PBMNC (19, 20), were evaluated by quantitative real-time PCR analysis. Both IL-1beta and A1 mRNA levels were induced by incubation with LPS and MDP in cells from individuals carrying normal or heterozygous NOD2 alleles (Fig. 3, D and E). In contrast, LPS but not MDP, increased the levels of both IL-1beta and A1 mRNA in PBMNC from individuals homozygous for L1007fsinsC (Fig. 3, D and E). Thus, PBMNC require the expression of normal NOD2 for their response to MDP but not to LPS. The lack of response to MDP in apparently normal individuals suggest that the presence of certain bacteria in the intestine and/or additional genetic factors may be required for clinical disease.

MDP is the minimal essential structure of bacterial peptidoglycan required for biological effects, including activity in Freund's complete adjuvant (21). MDP has been shown to signal through TLR2- and TLR4-independent mechanisms (22, 23), but the host recognition system for MDP has not been identified. We present evidence that NOD2 mediates the recognition of MDP in mammalian cells. Macrophages contain intracellular hydrolases that digest bacterial PGN and release PGN fragments including GlcNAc-MurNAc-dipeptide (24, 25). These muropeptides derived from intracellular and/or phagocytosed bacteria as well as PGN fragments released during bacterial growth would be available for recognition by NOD2. The synthetic MDP and GlcNAc-MurNAc-dipeptides mimicking the natural muropeptides induced NOD2-dependent activation of NF-kappa B. Thus, NOD2 is likely to be activated by muropeptides derived from bacteria in vivo. Although NOD2 can mediate the recognition of muropeptides, the mechanism involved is unclear and remains to be determined. Because the LRRs are required for recognition, muropeptides could interact directly with NOD2 through its LRRs or via as yet to be identified cellular factor(s). Crohn's disease-associated NOD2 variants and PBMNC from individuals homozygous for L1007fsinsC are defective in their response to muramyl dipeptide. This result is consistent with the observation that homozygocity for L1007fsinsC is needed for susceptibility to Crohn's disease (6, 7). Because activation of NF-kappa B in response to bacterial components mediates protection of the host against pathogens, NOD2-mediated susceptibility to disease may be caused by a failure to trigger a protective NF-kappa B pathway in response to muropeptides. Such a defective response against certain bacterial products may result secondarily in the diffuse activation of NF-kappa B found in intestinal tissue by NOD2-independent mechanisms. The results presented here suggest that restoring the activity against bacterial muropeptides may be beneficial to Crohn's disease patients harboring NOD2 mutations.

    ACKNOWLEDGEMENTS

We are grateful to T. Kirikae for stimulating discussions, C. Kirschning for HEK293-TLR2 cells, A. Zychlinsky for sBLP, and A. Hajjar for plasmids. We thank P. Lucas for critical review of the manuscript.

    FOOTNOTES

* This work was supported by National Institutes of Health Grants DK-61707 (to G. N.) and GM-60421 (to N. I.), a grant from Fundacion Marcelino Botin (to J. L. F.-L.), and by a postdoctoral fellowship from the Crohn's and Colitis Foundation of America (to Y. O.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

¶¶ These two authors share senior authorship.

|||| To whom correspondence should be addressed: University of Michigan Medical School, 1500 E. Medical Center Dr., 4219 CCGC, Ann Arbor, MI 48109. Tel.: 734-764-8514; Fax: 734-647-9654; E-mail: bclx@umich.edu.

Published, JBC Papers in Press, January 4, 2003, DOI 10.1074/jbc.C200673200

2 N. Inohara, Y. Ogura, and G. Nuñez, unpublished results.

    ABBREVIATIONS

The abbreviations used are: TLR, Toll-like receptor; LPS, lipopolysaccharide; MDP, muramyl dipeptide MurNAc-L-Ala-D-isoGln; NF-kappa B, nuclear factor-kappa B, PBMNC, peripheral blood mononuclear cells; PGN, peptidoglycan; sBLP, synthetic bacterial lipoprotein; HEK, human embryonic kidney; LRR, leucine-rich repeat; HA, hemagglutinin; IL, interleukin; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; EMSA, electrophoretic mobility shift assay; Mur, muramic acid.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS AND DISCUSSION
REFERENCES

1. Takeda, K., and Akira, S. (2001) Genes Cells 6, 733-742[Abstract/Free Full Text]
2. Inohara, N., Ogura, T., and Nuñez, G. (2002) Curr. Opin. Microbiol. 5, 76-80[CrossRef][Medline] [Order article via Infotrieve]
3. Girardin, S. E., Sansonetti, P. J., and Philpott, D. J. (2002) Trends Microbiol. 10, 193-199[CrossRef][Medline] [Order article via Infotrieve]
4. Ogura, Y., Inohara, N., Benito, A., Chen, F. F., Yamaoka, S., and Nuñez, G. (2001) J. Biol. Chem. 276, 4812-4818[Abstract/Free Full Text]
5. Gutierrez, O., Pipaon, C., Inohara, N., Fontalba, A., Ogura, Y., Prosper, F., Nuñez, G., and Fernandez-Luna, J. L. (2002) J. Biol. Chem. 277, 41701-47705[Abstract/Free Full Text]
6. Hugot, J. P., Chamaillard, M., Zouali, H., Lesage, S., Cezard, J. P., Belaiche, J., Almer, S., Tysk, C., O'Morain, C. A., Gassull, M., Binder, V., Finkel, Y., Cortot, A., Modigliani, R., Laurent-Puig, P., Gower-Rousseau, C., Macry, J., Colombel, J. F., Sahbatou, M., and Thomas, G. (2001) Nature 411, 599-603[CrossRef][Medline] [Order article via Infotrieve]
7. Ogura, Y., Bonen, D. K., Inohara, N., Nicolae, D. L., Chen, F. F., Ramos, R., Britton, H., Moran, T., Karaliuskas, R., Duerr, R. H., Achkar, J. P., Brant, S. R., Bayless, T. M., Kirschner, B. S., Hanauer, S. B., Nuñez, G, and Cho, J. H. (2001) Nature 411, 603-606[CrossRef][Medline] [Order article via Infotrieve]
8. Hampe, J., Cuthbert, A., Croucher, P. J., Mirza, M. M., Mascheretti, S., Fisher, S., Frenzel, H., King, K., Hasselmeyer, A., MacPherson, A. J., Bridger, S., van Deventer, S., Forbes, A., Nikolaus, S., Lennard-Jones, J. E., Foelsch, U. R., Krawczak, M., Lewis, C., Schreiber, S., and Mathew, C. G. (2001) Lancet 357, 1925-1928[CrossRef][Medline] [Order article via Infotrieve]
9. Ahmad, T., Armuzzi, A., Bunce, M., Mulcahy-Hawes, K., Marshall, S. E., Orchard, T. R., Crawshaw, J., Large, O., de Silva, A., Cook, J. T., Barnardo, M., Cullen, S., Welsh, K. I., and Jewell, D. P. (2002) Gastroenterology 122, 854-866[Medline] [Order article via Infotrieve]
10. Inohara, N., Ogura, Y., Chen, F. F., Muto, A., and Nuñez, G. (2001) J. Biol. Chem. 276, 2551-2554[Abstract/Free Full Text]
11. Hajjar, A. M., O'Mahony, D. S., Ozinsky, A., Underhill, D. M., Aderem, A., Klebanoff, S. J., and Wilson, C. B. (2002) J. Immunol. 166, 15-19[Abstract/Free Full Text]
12. Onishi, M., Kinoshita, S., Morikawa, Y., Shibuya, A., Phillips, J., Lanier, L. L., Gorman, D. M., Nolan, G. P., Miyajima, A., and Kitamura, T. (1996) Exp. Hematol. 24, 324-329[Medline] [Order article via Infotrieve]
13. Takeuchi, O., Hoshino, K., Kawai, T., Sanjo, H., Takada, H., Ogawa, T., Takeda, K., and Akira, S. (1999) Immunity 11, 443-451[Medline] [Order article via Infotrieve]
14. Atrih, A., Bacher, G., Allmaier, G., Williamson, M. P., and Foster, S. J. (1999) J. Bacteriol. 181, 3956-3962[Abstract/Free Full Text]
15. Glauner, B., Höltje, J.-V., and Schwartz, U. (1988) J. Biol. Chem. 263, 10088-10095[Abstract/Free Full Text]
16. Inamura, S., Fukase, K., and Kusumoto, S. (2001) Tetrahedron Lett. 42, 7613-7619[CrossRef]
17. Aliprantis, A. O., Yang, R. B., Mark, M. R., Suggett, S., Devaux, B., Radolf, J. D., Klimpel, G. R., Godowski, P., and Zychlinsky, A. (1999) Science 285, 736-739[Abstract/Free Full Text]
18. Lee, H. K., and Tobias, P. S. (2002) J. Immunol. 168, 4012-4017[Abstract/Free Full Text]
19. Cogswell, J. P., Godlevski, M. M., Wisely, G. B., Clay, W. C., Leesnitzer, L. M., Ways, J. P., and Gray, J. G. (1994) J. Immunol. 153, 712-723[Abstract/Free Full Text]
20. Zong, W. X., Edelstein, L. C., Chen, C., Bash, J., and Gelinas, C. (1999) Genes Dev. 13, 382-387[Abstract/Free Full Text]
21. Takada, H., and Kotani, S. (1995) in The Theory and Practical Application of Adjuvants (Stewart, D. E. S., ed) , pp. 171-202, Wiley, Chichester, UK
22. Yang, S., Tamai, R., Akashi, S., Takeuchi, O., Akira, S., Sugawara, S., and Takada, H. (2001) Infect. Immun. 69, 2045-2053[Abstract/Free Full Text]
23. Wolfert, M. A., Murray, T. F., Boons, G.-J, and Moore, J. N. (2002) J. Biol. Chem. 277, 39179[Abstract/Free Full Text]-
24. Johannsen, L., Wecke, J., Obal, F., Jr., and Krueger, J. M. (1991) Am. J. Physiol. 260, R126-R133[Abstract/Free Full Text]
25. Vermeulen, M. W., and Gray, G. R. (1984) Infect. Immun. 46, 476-483[Medline] [Order article via Infotrieve]


Copyright © 2003 by The American Society for Biochemistry and Molecular Biology, Inc.